Trial Profile
Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Hyaluronidase (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 22 Jan 2022 Status changed from recruiting to discontinued as per results presented at the 2022 Gastrointestinal Cancers Symposium
- 22 Jan 2022 Results presented at the 2022 Gastrointestinal Cancers Symposium
- 25 Jan 2020 Trial design of Phase II study of PEGPH20 plus pembrolizumab for patients with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma has been presented at the 2020 Gastrointestinal Cancers Symposium